480 STUDY: Phase 2b Study of Locteron Plus Ribavirin to Treat Hepatitis C Virus (HCV)

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2009
The purpose of this 12-week study was to assess in subjects with chronic hepatitis C (treatment-naïve, genotype 1) receiving weight-based doses of ribavirin the early virologic response to the 480 ug dose level of Locteron™, dosed every 2 weeks, in comparison with 1.5 ug/kg PEG-Intron™ dosed weekly.
Epistemonikos ID: 3a7e5e51581de4fa38e23d993920130f64ec2d3a
First added on: Mar 23, 2020